In Vitro Activity of Ertapenem Versus Ceftriaxone Against Neisseria Gonorrhoeae Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea?

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2012 May 2

PMID 22547617

Citations 26

Authors

Magnus Unemo

Daniel Golparian

Athena Limnios

David Whiley

Makoto Ohnishi

Monica M Lahra

John W Tapsall

Affiliations

Soon will be listed here.

Abstract

Clinical resistance to the currently recommended extended-spectrum cephalosporins (ESCs), the last remaining treatment options for gonorrhea, is being reported. Gonorrhea may become untreatable, and new treatment options are crucial. We investigated the in vitro activity of ertapenem, relative to ceftriaxone, against N. gonorrhoeae isolates and the effects of ESC resistance determinants on ertapenem. MICs were determined using agar dilution technique or Etest for international reference strains (n = 17) and clinical N. gonorrhoeae isolates (n = 257), which included the two extensively drug-resistant (XDR) strains H041 and F89 and additional isolates with high ESC MICs, clinical ESC resistance, and other types of clinical high-level and multidrug resistance (MDR). Genetic resistance determinants for ESCs (penA, mtrR, and penB) were sequenced. In general, the MICs of ertapenem (MIC(50) = 0.032 μg/ml; MIC(90) = 0.064 μg/ml) paralleled those of ceftriaxone (MIC(50) = 0.032 μg/ml; MIC(90) = 0.125 μg/ml). The ESC resistance determinants mainly increased the ertapenem MIC and ceftriaxone MIC at similar levels. However, the MIC ranges for ertapenem (0.002 to 0.125 μg/ml) and ceftriaxone (<0.002 to 4 μg/ml) differed, and the four (1.5%) ceftriaxone-resistant isolates (MIC = 0.5 to 4 μg/ml) had ertapenem MICs of 0.016 to 0.064 μg/ml. Accordingly, ertapenem had in vitro advantages over ceftriaxone for isolates with ceftriaxone resistance. These in vitro results suggest that ertapenem might be an effective treatment option for gonorrhea, particularly for the currently identified ESC-resistant cases and possibly in a dual antimicrobial therapy regimen. However, further knowledge regarding the genetic determinants (and their evolution) conferring resistance to both antimicrobials, and clear correlates between genetic and phenotypic laboratory parameters and clinical treatment outcomes, is essential.

Citing Articles

Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae.

Lopez-Arguello S, Alcoceba E, Ordonez P, Taltavull B, Cabot G, Gomis-Font M PLoS Pathog. 2024; 20(12):e1012783.

PMID: 39739989 PMC: 11729944. DOI: 10.1371/journal.ppat.1012783.

Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions.

Allan-Blitz L, Fifer H, Klausner J Lancet Infect Dis. 2024; 24(8):e532-e538.

PMID: 38367636 PMC: 11391204. DOI: 10.1016/S1473-3099(24)00001-X.

Increase in Multidrug Resistant FC428-Like Isolates Harboring the Mosaic penA 60.001 Gene, in Nanjing, China (2017-2020).

Zhao Y, Le W, Genco C, Rice P, Su X Infect Drug Resist. 2023; 16:4053-4064.

PMID: 37383603 PMC: 10295622. DOI: 10.2147/IDR.S408896.

Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae.

Lopez-Arguello S, Montaner M, Marmol-Salvador A, Velazquez-Escudero A, Docobo-Perez F, Oliver A Microbiol Spectr. 2023; 11(3):e0069223.

PMID: 37093051 PMC: 10269775. DOI: 10.1128/spectrum.00692-23.

Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019).

Li X, Le W, Lou X, Genco C, Rice P, Su X Antimicrob Agents Chemother. 2022; 66(5):e0010922.

PMID: 35491832 PMC: 9112910. DOI: 10.1128/aac.00109-22.

References

Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H . Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis. 2011; 17(1):148-9. PMC: 3204624. DOI: 10.3201/eid1701.100397. View

Livermore D, Alexander S, Marsden B, James D, Warner M, Rudd E . Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother. 2004; 54(1):280-1. DOI: 10.1093/jac/dkh272. View

Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods G . A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002; 60(1):16-22. DOI: 10.1016/s0090-4295(02)01664-3. View

Unemo M, Golparian D, Syversen G, Vestrheim D, Moi H . Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 2010; 15(47). DOI: 10.2807/ese.15.47.19721-en. View

Zarantonelli L, Borthagaray G, Lee E, Shafer W . Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother. 1999; 43(10):2468-72. PMC: 89502. DOI: 10.1128/AAC.43.10.2468. View

Ison C, Hussey J, Sankar K, Evans J, Alexander S . Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011; 16(14). View

Olesky M, Zhao S, Rosenberg R, Nicholas R . Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol. 2006; 188(7):2300-8. PMC: 1428387. DOI: 10.1128/JB.188.7.2300-2308.2006. View

Takahata S, Senju N, Osaki Y, Yoshida T, Ida T . Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2006; 50(11):3638-45. PMC: 1635225. DOI: 10.1128/AAC.00626-06. View

Unemo M, Shafer W . Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci. 2012; 1230:E19-28. PMC: 4510988. DOI: 10.1111/j.1749-6632.2011.06215.x. View

10.

Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y . Threat to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007; 13(8):1275-7. PMC: 2828067. DOI: 10.3201/eid1308.060948. View

11.

Tomberg J, Unemo M, Davies C, Nicholas R . Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry. 2010; 49(37):8062-70. PMC: 2939205. DOI: 10.1021/bi101167x. View

12.

. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Commun Dis Intell Q Rep. 2011; 35(1):2-7. View

13.

Tapsall J, Phillips E . The sensitivity of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhea. Pathology. 1995; 27(1):64-6. DOI: 10.1080/00313029500169492. View

14.

Putnam S, Castanheira M, Moet G, Farrell D, Jones R . CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis. 2009; 66(4):393-401. DOI: 10.1016/j.diagmicrobio.2009.10.013. View

15.

Deguchi T, Yasuda M, Yokoi S, Ishida K, Ito M, Ishihara S . Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 2003; 9(1):35-9. DOI: 10.1007/s10156-002-0204-8. View

16.

Barry P, Klausner J . The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother. 2009; 10(4):555-77. PMC: 2657229. DOI: 10.1517/14656560902731993. View

17.

Unemo M, Golparian D, Stary A, Eigentler A . First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 2011; 16(43). View

18.

Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A . Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol. 2009; 58(Pt 5):683-687. DOI: 10.1099/jmm.0.007641-0. View

19.

Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J . Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009; 63(6):1142-51. DOI: 10.1093/jac/dkp098. View

20.

Martin I, Jayaraman G, Wong T, Liu G, Gilmour M . Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex Transm Dis. 2011; 38(10):892-8. DOI: 10.1097/OLQ.0b013e31822c664f. View